MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Начало・Списък с акции・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Затворен

СекторЗдравеопазване

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-0.05% downside

Настроения в новините

By Acuity

43%

57%

149 / 348 Класиране в Healthcare

Mirati Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.04.2026 г., 20:26 ч. UTC

Придобивния, сливания и поглъщания

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17.04.2026 г., 18:15 ч. UTC

Значими събития в новините

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17.04.2026 г., 16:49 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17.04.2026 г., 16:49 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17.04.2026 г., 22:58 ч. UTC

Печалби

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17.04.2026 г., 21:32 ч. UTC

Пазарно говорене

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17.04.2026 г., 21:22 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.04.2026 г., 21:22 ч. UTC

Пазарно говорене

Moody's Downgrades Belgium to A1 -- Market Talk

17.04.2026 г., 20:52 ч. UTC

Печалби

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

17.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.04.2026 г., 20:29 ч. UTC

Печалби

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

UCB to Buy Neurona Therapeutics for Up to $1.15B

17.04.2026 г., 19:34 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

17.04.2026 г., 19:34 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17.04.2026 г., 19:31 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17.04.2026 г., 19:26 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Edge Up -- Market Talk

17.04.2026 г., 19:21 ч. UTC

Пазарно говорене

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17.04.2026 г., 19:07 ч. UTC

Пазарно говорене

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17.04.2026 г., 18:57 ч. UTC

Значими събития в новините

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17.04.2026 г., 18:53 ч. UTC

Придобивния, сливания и поглъщания

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17.04.2026 г., 18:53 ч. UTC

Придобивния, сливания и поглъщания

UCB 2026 Rev Guidance Unchanged

17.04.2026 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17.04.2026 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17.04.2026 г., 18:14 ч. UTC

Пазарно говорене

Значими събития в новините

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17.04.2026 г., 18:00 ч. UTC

Значими събития в новините

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17.04.2026 г., 18:00 ч. UTC

Значими събития в новините

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17.04.2026 г., 17:31 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17.04.2026 г., 17:26 ч. UTC

Пазарно говорене

Печалби

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Mirati Therapeutics Inc Прогноза

Ценова цел

By TipRanks

-0.05% надолу

12-месечна прогноза

Среден 58.67 USD -0.05%

Висок 59 USD

Нисък 58 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Mirati Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Mirati Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

149 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.